Home Cart 0 Sign in  

[ CAS No. 21691-44-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 21691-44-1
Chemical Structure| 21691-44-1
Structure of 21691-44-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 21691-44-1 ]

Related Doc. of [ 21691-44-1 ]

Alternatived Products of [ 21691-44-1 ]

Product Details of [ 21691-44-1 ]

CAS No. :21691-44-1 MDL No. :MFCD00063167
Formula : C13H17NO4 Boiling Point : -
Linear Structure Formula :- InChI Key :NSJDRLWFFAWSFP-NSHDSACASA-N
M.W : 251.28 Pubchem ID :6993399
Synonyms :

Calculated chemistry of [ 21691-44-1 ]

Physicochemical Properties

Num. heavy atoms : 18
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.38
Num. rotatable bonds : 8
Num. H-bond acceptors : 4.0
Num. H-bond donors : 2.0
Molar Refractivity : 66.5
TPSA : 75.63 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.19 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.76
Log Po/w (XLOGP3) : 2.32
Log Po/w (WLOGP) : 2.01
Log Po/w (MLOGP) : 1.7
Log Po/w (SILICOS-IT) : 1.56
Consensus Log Po/w : 1.87

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -2.58
Solubility : 0.664 mg/ml ; 0.00264 mol/l
Class : Soluble
Log S (Ali) : -3.55
Solubility : 0.0713 mg/ml ; 0.000284 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.17
Solubility : 0.171 mg/ml ; 0.000681 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.69

Safety of [ 21691-44-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 21691-44-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 21691-44-1 ]
  • Downstream synthetic route of [ 21691-44-1 ]

[ 21691-44-1 ] Synthesis Path-Upstream   1~7

  • 1
  • [ 501-53-1 ]
  • [ 950842-17-8 ]
  • [ 21691-44-1 ]
YieldReaction ConditionsOperation in experiment
70%
Stage #1: With hydrogenchloride; water In tetrahydrofuran at 20℃;
Stage #2: With lithium hydroxide; water In tetrahydrofuran at 20℃;
Stage #3: at 0℃; for 1.25 h;
Compound vii (15.39 g, 32.1 mmol) from step a was charged into THF (100 mL) and 1N HCl (50 mL). The resulting emulsion was stirred overnight at the room temperature and then concentrated under vacuum to provide a thick oil. The oil was then dissolved in THF (100 mL), and to the solution was added water (25 mL) and LiOH (3.08 g, 128 mmol). This solution was stirred overnight again at the room temperature and then concentrated to remove THF. A hazy light yellow emulsion remained. This was diluted with water (25 mL) and extracted with CH2Cl2 (three times, 50 mL each). The aqueous phase was diluted with THF (200 mL) and cooled to 0° C. while stirring rapidly and CBZ-Cl (7.6 mL, 54 mmol) was added dropwise over 15 minutes. After stirring for an hour at 0° C., the THF solvent was removed in vacuo and the residue was acidified by addition of 1N HCl (50 mL). The solution was extracted with EtOAc (3 times, 100 mL each) and the organic phase was dried over Na2SO4 and concentrated to provide an oil. The residue was dissolved in EtOAc (25 mL) and heptane (150 mL), seeded and stirred overnight at the room temperature. The solids were collected on a flit, rinsed with heptane (30 mL) and air dried to give 5.65 g (70percent) of compound viii shown in the scheme above. The deuterium incorporation was 93percent as determined by 1H NMR.
Reference: [1] Patent: US2007/225297, 2007, A1, . Location in patent: Page/Page column 16
  • 2
  • [ 134306-33-5 ]
  • [ 21691-44-1 ]
Reference: [1] Journal of the Chinese Chemical Society, 1999, vol. 46, # 5, p. 647 - 650
  • 3
  • [ 6600-40-4 ]
  • [ 501-53-1 ]
  • [ 21691-44-1 ]
Reference: [1] Journal of Medicinal Chemistry, 1986, vol. 29, # 1, p. 29 - 40
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4815 - 4830
[3] Bioorganic and Medicinal Chemistry, 2001, vol. 9, # 5, p. 1213 - 1219
  • 4
  • [ 101650-08-2 ]
  • [ 21691-44-1 ]
Reference: [1] Canadian Journal of Chemistry, 2008, vol. 86, # 3, p. 219 - 224
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 62 - 65
  • 5
  • [ 93712-83-5 ]
  • [ 21691-44-1 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 62 - 65
  • 6
  • [ 6600-40-4 ]
  • [ 21691-44-1 ]
Reference: [1] Journal of Biochemistry (Tokyo, Japan), 1959, vol. 46, p. 19,21
  • 7
  • [ 21691-43-0 ]
  • [ 21691-44-1 ]
  • [ 42918-89-8 ]
Reference: [1] Chemistry Letters, 1988, p. 1125 - 1128
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 21691-44-1 ]

Amino Acid Derivatives

Chemical Structure| 218938-55-7

[ 218938-55-7 ]

(S)-2-(((Benzyloxy)carbonyl)amino)-6-(isopropylamino)hexanoic acid

Similarity: 0.98

Chemical Structure| 25341-42-8

[ 25341-42-8 ]

(S)-2-(((Benzyloxy)carbonyl)amino)-3-cyclohexylpropanoic acid

Similarity: 0.98

Chemical Structure| 27025-24-7

[ 27025-24-7 ]

(R)-2-(((Benzyloxy)carbonyl)amino)-5-methoxy-5-oxopentanoic acid

Similarity: 0.98

Chemical Structure| 28862-79-5

[ 28862-79-5 ]

Z-D-Leu-OH

Similarity: 0.98

Chemical Structure| 4652-65-7

[ 4652-65-7 ]

Z-Glu(OMe)-OH

Similarity: 0.98